FibroBiologics, Inc. (Nasdaq:FBLG)
Health Care/Life Sciences • Biotechnology
CIK 1958777
Company
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.
Address
455 East Medical Center Boulevard
Suite 300
Houston, Texas 77598
455 East Medical Center Boulevard
Suite 300
Houston, Texas 77598
Employees
10
10
Key Executives
Board Of Directors
|
Independent Director Robert E Hoffman CPA |
|
Independent Director Matthew W Link |
|
Independent Director Victoria Niklas MD |
|
Independent Director Richard C Cilento Jr., MBA |
|
Independent Director Stacy A Coen MBA |
SEC filings
| Date | Form | Event |
|---|---|---|
| 20 Dec, 2024 | 8-K | |
| 9 Dec, 2024 | 4 | |
| 5 Dec, 2024 | 4 | |
| 12 Nov, 2024 | 10-Q | |
| 29 Oct, 2024 | 8-K | |
| 24 Sep, 2024 | 8-K | |
| 28 Aug, 2024 | 8-K | |
| 27 Aug, 2024 | 4 | |
| 27 Aug, 2024 | 4 | |
| 27 Aug, 2024 | 8-K | |
| 27 Aug, 2024 | 4 | |
| 27 Aug, 2024 | 4 | |
| 27 Aug, 2024 | 4 | |
| 14 Aug, 2024 | EFFECT | |
| 13 Aug, 2024 | 3/A | |
| 13 Aug, 2024 | 3/A | |
| 13 Aug, 2024 | 3/A | |
| 13 Aug, 2024 | POS AM | |
| 13 Aug, 2024 | 3/A | |
| 13 Aug, 2024 | 3/A | |
| 13 Aug, 2024 | 3/A | |
| 12 Aug, 2024 | 3/A | |
| 12 Aug, 2024 | 3/A | |
| 12 Aug, 2024 | 4 | |
| 12 Aug, 2024 | 4 | |
| 7 Aug, 2024 | 10-Q | |
| 8 Jul, 2024 | DEF 14A | |
| 8 Jul, 2024 | ARS | |
| 8 Jul, 2024 | DEFA14A | |
| 27 Jun, 2024 | 8-K | |
| 27 Jun, 2024 | PRE 14A | |
| 26 Jun, 2024 | 424B4 | |
| 25 Jun, 2024 | EFFECT | |
| 21 Jun, 2024 | CORRESP | |
| 21 Jun, 2024 | CORRESP | |
| 18 Jun, 2024 | S-1 | |
| 18 Jun, 2024 | CORRESP | |
| 17 Jun, 2024 | UPLOAD | |
| 10 Jun, 2024 | DRS | |
| 6 Jun, 2024 | RW | |
| 4 Jun, 2024 | S-1/A | |
| 15 May, 2024 | S-1/A | |
| 15 May, 2024 | S-8 | |
| 14 May, 2024 | 10-Q | |
| 26 Apr, 2024 | S-1 | |
| 26 Apr, 2024 | 8-K | |
| 12 Apr, 2024 | DRS | |
| 28 Mar, 2024 | 424B4 | |
| 28 Mar, 2024 | EFFECT | |
| 27 Mar, 2024 | CORRESP | |
| 26 Mar, 2024 | CORRESP | |
| 26 Mar, 2024 | S-1/A | |
| 25 Mar, 2024 | UPLOAD | |
| 15 Mar, 2024 | CORRESP | |
| 15 Mar, 2024 | S-1/A | |
| 8 Mar, 2024 | 4 | |
| 6 Mar, 2024 | 3 | |
| 29 Feb, 2024 | 10-K | |
| 26 Feb, 2024 | UPLOAD | |
| 20 Feb, 2024 | 8-K | |
| 15 Feb, 2024 | 3 | |
| 14 Feb, 2024 | 8-K | |
| 13 Feb, 2024 | 3 | |
| 13 Feb, 2024 | 3 | |
| 12 Feb, 2024 | S-1 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 8-K | |
| 8 Feb, 2024 | 3 | |
| 7 Feb, 2024 | 3 | |
| 7 Feb, 2024 | 3 | |
| 7 Feb, 2024 | 3 | |
| 6 Feb, 2024 | 8-K | |
| 2 Feb, 2024 | 8-K | |
| 31 Jan, 2024 | 424B4 | IPO completed |
| 30 Jan, 2024 | CERT | |
| 24 Jan, 2024 | S-1/A | |
| 24 Jan, 2024 | EFFECT | |
| 24 Jan, 2024 | S-1/A | |
| 24 Jan, 2024 | 8-A12B | |
| 22 Jan, 2024 | CORRESP | |
| 22 Jan, 2024 | S-1/A | |
| 16 Jan, 2024 | CORRESP | |
| 12 Jan, 2024 | S-1/A | |
| 14 Dec, 2023 | FWP | |
| 7 Dec, 2023 | S-1/A | |
| 4 Dec, 2023 | S-1/A | |
| 30 Nov, 2023 | S-1/A | |
| 28 Nov, 2023 | S-1/A | |
| 7 Nov, 2023 | CORRESP | |
| 7 Nov, 2023 | S-1 | |
| 27 Oct, 2023 | UPLOAD | |
| 13 Oct, 2023 | DRS/A | |
| 13 Oct, 2023 | DRSLTR | |
| 11 Sep, 2023 | UPLOAD | |
| 16 Aug, 2023 | DRSLTR | |
| 16 Aug, 2023 | DRS/A | |
| 23 Jun, 2023 | UPLOAD | |
| 18 May, 2023 | DRS | |
| 1 May, 2023 | C-AR | |
| 11 Apr, 2023 | C-U | |
| 29 Mar, 2023 | C/A | |
| 10 Feb, 2023 | C/A | |
| 31 Jan, 2023 | C |
Last update:2024-03-12 12:03:55.354482
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.